Does Geography and Place of Residence Affect Cancer Care: An Interview Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03836794 |
|
Recruitment Status :
Completed
First Posted : February 11, 2019
Last Update Posted : February 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Cancer |
Show detailed description
| Study Type : | Observational |
| Actual Enrollment : | 20 participants |
| Observational Model: | Other |
| Time Perspective: | Prospective |
| Official Title: | Does Geography and Place of Residence Affect Cancer Care: An Interview Study |
| Actual Study Start Date : | March 3, 2019 |
| Actual Primary Completion Date : | March 3, 2020 |
| Actual Study Completion Date : | March 3, 2020 |
- Qualitive Measures of a Study Questionnaire [ Time Frame: 1 year ]Interviewing 25 patients, rich, explanatory qualitative data from patients about their path to diagnosis and their path to treatment and how that may have been influenced by where they live.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients will be eligible to participate if they are adults, 18 years or over, confirmed cancer diagnosis from the top eight cancer sites (lung, oesophageal, colorectal, breast, pancreatic, prostate, kidney, and bladder) within the last 2 years. Participants can have all stages and all grades of cancer as long as they feel able to provide a full interview for approximately 45 minutes. There will be an opportunity for patient to opt into telephone interviews. Interviewees are able to stop their interviews at any moment without having to give a reason.
Exclusion Criteria:
- The research team involved in recruiting will exclude patients that are unable to give consent, non-English speaking patients, patients under the age of 18 and patients that are too ill based on the observation of the clinical staff.
This study will exclude persons who have difficulty understanding verbal explanations in English. This study is a small qualitative study based upon interviews conducted by a single researcher in the English language. The analysis of the data will depend upon specific words and utterances which are used by the participant. Meaning will be derived from words, phrases, and utterances and will be reliant upon the participant being able to communicate in the English language.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03836794
| United Kingdom | |
| Aberdeen Royal Infirmary | |
| Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZN | |
| Principal Investigator: | Romi A Carriere, MPH | University of Aberdeen |
| Responsible Party: | University of Aberdeen |
| ClinicalTrials.gov Identifier: | NCT03836794 |
| Other Study ID Numbers: |
2-109-18 |
| First Posted: | February 11, 2019 Key Record Dates |
| Last Update Posted: | February 18, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |

